Skip to content

Dexamethasone to Prevent Side Effects of Spinal Anesthesia in Cesarean Delivery

Evaluation of the Effectiveness of Intravenous Dexamethasone in Preventing Adverse Effects of Spinal Anesthesia in Parturients Undergoing Cesarean Delivery

Status
Enrolling by invitation
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07615595
Enrollment
176
Registered
2026-05-29
Start date
2025-08-01
Completion date
2027-07-31
Last updated
2026-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypotension During Cesarean Delivery, Pain, Postoperative, Postoperative Nausea and Vomiting (PONV)

Keywords

Dexamethasone, Prophylaxis, Elective Cesarean Delivery, Spinal-induced Hypotension, Postoperative Analgesia, Parturients

Brief summary

The goal of this clinical trial is to evaluate the effectiveness of intravenous dexamethasone in preventing adverse effects of spinal anesthesia and prolonging postoperative analgesia in parturients undergoing elective cesarean delivery. The main questions it aims to answer are: Does intravenous dexamethasone reduce the incidence of post-spinal hypotension? Does intravenous dexamethasone reduce the incidence of postoperative nausea and vomiting (PONV)? Does intravenous dexamethasone prolong the duration of postoperative analgesia? Researchers will compare intravenous dexamethasone (8 mg) to a placebo (0.9% saline) to see if dexamethasone effectively prevents post-spinal hypotension and PONV, and improves postoperative pain relief. Participants will: Receive an intravenous injection of either 8 mg dexamethasone or a placebo (2 mL 0.9% saline) prior to receiving spinal anesthesia. Have their blood pressure recorded frequently (every minute for the first 20 minutes, then every 5 minutes until the completion of surgery). Undergo sensory block assessment (via cold testing) and motor block evaluation (using the Bromage scale). Have maternal glycemia and neonatal safety monitored for potential steroid-related adverse effects.

Interventions

DRUGDexamethasone

Intravenous administration of 8 mg dexamethasone immediately before the induction of spinal anesthesia.

OTHERPlacebo

Intravenous administration of 2 mL of 0.9% normal saline as a placebo immediately before the induction of spinal anesthesia.

Sponsors

University Medical Center Ho Chi Minh City (UMC)
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Intervention model description

Prospective, randomized, placebo-controlled, single-blind, parallel-group clinical trial

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years * Singleton pregnancy * Gestational age ≥ 37 weeks * American Society of Anesthesiologists (ASA) physical status classification of II-III * Planned for elective cesarean delivery under spinal anesthesia

Exclusion criteria

* Gestational diabetes mellitus or pre-existing (chronic) diabetes mellitus * Gestational hypertension or chronic hypertension * Body mass index (BMI) ≥ 35 kg/m² * Known allergy to dexamethasone * Current long-term corticosteroid therapy * Diagnosis of postpartum hemorrhage

Design outcomes

Primary

MeasureTime frameDescription
Incidence of Post-Spinal HypotensionFrom the induction of spinal anesthesia until the completion of surgeryThe number of participants experiencing at least one episode of post-spinal hypotension. Hypotension is defined as a decrease in systolic blood pressure of 20% or more from the baseline value. Baseline blood pressure is defined as the mean value of three consecutive measurements taken 2 minutes apart, with a variation of less than 10%. Systolic blood pressure, diastolic blood pressure, mean arterial pressure, and heart rate are recorded every minute for the first 20 minutes after spinal anesthesia, and then every 5 minutes until the completion of surgery and transfer to the post-anesthesia care unit

Secondary

MeasureTime frameDescription
Incidence of Postoperative Nausea and Vomiting (PONV)From the induction of spinal anesthesia until discharge from the post-anesthesia care unit (PACU) (estimated up to 6 hours)The number of participants experiencing nausea, vomiting, or retching, or requiring rescue antiemetic treatment. Rescue treatment is administered as intravenous ondansetron 4 mg or intravenous metoclopramide 10 mg.
Duration of Postoperative AnalgesiaFrom the administration of spinal anesthesia until the first request for rescue analgesia (estimated up to 24 hours)The time elapsed from the administration of spinal anesthesia to the patient's first request for systemic rescue analgesic medication. Rescue analgesia is administered when the patient complains of pain and records a Visual Analog Scale (VAS) score greater than 4 (on a scale of 0 to 10).

Countries

Vietnam

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 30, 2026